Emerging data suggest this peptide, a dual agonist targeting both the gut-brain axis and GIP , appears to provide a significant development here for body loss . Early human investigations have shown impressive losses in abdominal fat , conceivably exceeding current body composition treatments. However , additional study is necessary to thoroughly a